AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Follow-Up Questions
Who is the CEO of AIM ImmunoTech Inc?
Mr. Thomas Equels is the President of AIM ImmunoTech Inc, joining the firm since 2008.
What is the price performance of AIM stock?
The current price of AIM is $2.62, it has increased 0.38% in the last trading day.
What are the primary business themes or industries for AIM ImmunoTech Inc?
AIM ImmunoTech Inc belongs to Biotechnology industry and the sector is Health Care
What is AIM ImmunoTech Inc market cap?
AIM ImmunoTech Inc's current market cap is $7.1M
Is AIM ImmunoTech Inc a buy, sell, or hold?
According to wall street analysts, 2 analysts have made analyst ratings for AIM ImmunoTech Inc, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
